Conservative Management of CIN2 Lesions and Biomarkers Evaluation
Launched by ISTITUTO ONCOLOGICO VENETO IRCCS · Dec 23, 2020
Trial Information
Current as of June 12, 2025
Completed
Keywords
ClinConnect Summary
Women aged 25-45 years, adherent to the organized population-based cervical screening program, with a histological diagnosis of CIN2 and fulfilling the inclusion criteria will be invited to participate to the study, previously providing specific information; in case of acceptance, informed consent is signed.
STUDY PROTOCOL:
The adherent women will attend periodical control visits:
* every 6 months up to 24 months, with performance of: pap test (PT) and colposcopy (with biopsy in case of visible alterations);
* at 6 and 12 months control visit: a liquid-based sample of cervical cells will...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • age range 25-45 years,
- • CIN2 lesions located in the exocervix and completely visible at colposcopy.
- Exclusion Criteria:
- • age \>45 years;
- • history of previous high-grade lesions;
- • squamo-columnar junction not completely visible (type 3);
- • cytology with suspect or indicative for invasive lesion;
- • lesions exclusively located in the endocervix;
- • lesions located in the exocervix but not completely visible;
- • pregnancy
About Istituto Oncologico Veneto Irccs
Istituto Oncologico Veneto IRCCS is a leading cancer research and treatment institution located in Italy, dedicated to advancing oncological science and improving patient outcomes. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it combines clinical excellence with cutting-edge research, focusing on innovative therapies and comprehensive cancer care. The institute plays a pivotal role in the development and execution of clinical trials, fostering collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective treatment strategies. Through its commitment to high-quality research and patient-centered care, Istituto Oncologico Veneto IRCCS aims to enhance the understanding and treatment of cancer on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Padova, Pd, Italy
Treviso, Tv, Italy
Mestre, Ve, Italy
Verona, Vr, Italy
Patients applied
Trial Officials
Tiziano Maggino, MD
Principal Investigator
Azienda ULSS 3 Serenissima
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials